A Korean research team jointly led by Professor Chan Beum Park of the Materials Science and Engineering Department at KAIST and Dr. Kwon Yu from the Bionano Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) conducted research to suppress an abnormal assembly of beta-amyloids, a protein commonly found in the brain, by using photo-excited porphyrins.
Beta-amyloid plaques are known to cause Alzheimer’s disease. This research finding suggests new ways to treat neurodegenerative illnesses including Alzheimer’s disease. It was published online as the lead article in the September 21th issue of Angewandte Chemie. The title of the article is “Photo-excited Porphyrins as a Strong Suppressor of ß-Amyloid Aggregation and Synaptic Toxicity.”
Light-induced treatments using organic photosensitizers have advantages to managing the treatment in time and area. In the case of cancer treatments, doctors use photodynamic therapies where a patient is injected with an organic photosensitizer, and a light is shed on the patient’s lesion. However, such therapies had never been employed to treat neurodegenerative diseases.
Alzheimer’s starts when a protein called beta-amyloid is created and deposited in a patient’s brain. The abnormally folded protein created this way harms the brain cells by inducing the degradation of brain functions, for example, dementia. If beta-amyloid creation can be suppressed at an early stage, the formation of amyloid deposits will stop. This could prevent Alzheimer’s disease or halt its progress.
The research team effectively prevented the buildup of beta-amyloids by using blue LED lights and a porphyrin inducer, which is a biocompatible organic compound. By absorbing light energy, a photosensitizer such as porphyrin reaches the excitation state. Active oxygen is created as the porphyrin returns to its ground state. The active oxygen oxidizes a beta-amyloid monomer, and by combining with it, disturbs its assembly.
The technique was tested on drosophilae or fruit flies, which were produced to model Alzheimer on invertebrates. The research showed that symptoms of Alzheimer’s disease in the fruit flies such as damage on synapse and muscle, neuronal apoptosis, degradation in motility, and decreased longevity were alleviated. Treatments with light provide additional benefits: less medication is needed than other drug treatments, and there are fewer side effects. When developed, photodynamic therapy will be used widely for this reason.
Professor Park said,
“This work has significance as it was the first case to use light and photosensitizers to stop deposits of beta-amyloids. We plan to carry the research further by testing compatibility with other organic and inorganic photosensitizers and by changing the subject of photodynamic therapy to vertebrate such as mice.”
Read more: Using Light to Treat Alzheimer’s Disease
The Latest on: Photodynamic therapy
via Google News
The Latest on: Photodynamic therapy
- Global Actinic Keratosis Treatment Market Research Report 2021on December 3, 2021 at 7:00 am
The "Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Surgery, Photodynamic Therapy), By Drug Class, ...
- Biofrontera Shares Drop 17% After Thursday's Riseon December 3, 2021 at 6:48 am
By Chris Wack Biofrontera Inc. shares were down 17% to $4.36 Friday, one day after the company said the U.S. Patent and Trademark Office issued a notice ...
- BFRI Stock: The News That Has Biofrontera Shares Bounding Higher Todayon December 2, 2021 at 2:38 pm
Biofrontera (BFRI) stock is getting a boost on Thursday thanks to an update from the United States Patent and Trademark Office.
- Why Are Biofrontera Shares Surging Today?on December 2, 2021 at 10:36 am
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Inc (NASDAQ: BFRI) titled "Illumination for Photodynamic Therapy." The patent covers ...
- Global Actinic Keratosis Treatment Markets, 2017-2020 & 2021-2028 by Therapy, Drug Class, & End-Use - ResearchAndMarkets.comon December 2, 2021 at 7:26 am
The "Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Surgery, Photodynamic Therapy), By Drug Class, By End-Use (Hospitals, Homecare), By Region, And Segment ...
- Biofrontera Shares Rise 22% After Notice of Allowance for U.S. Patenton December 2, 2021 at 6:19 am
By Chris Wack Biofrontera Inc. shares were up 22% to $5.27 Thursday after the company said the U.S. Patent and Trademark Office issued a notice of ...
- Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocolon December 2, 2021 at 6:15 am
Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO ...
- A UT Arlington researcher is testing a new option for cancer patients: Photodynamic therapyon November 29, 2021 at 10:00 am
Also called PDT, the FDA-approved therapy uses drugs activated by light to target and destroy tumor cells. A chemistry professor at UT Arlington and her team have developed a chemical compound using ...
- Cancer Photodynamic Therapy Marketon November 28, 2021 at 3:07 pm
Global Cancer Photodynamic Therapy Market Synopsis: The credible Cancer Photodynamic Therapy Market report, like other reports, follows certain process flow with several steps. First is product ...
- Oxygen-delivering nanodroplets enhance the efficacy of photodynamic therapyon November 27, 2021 at 12:12 pm
Treatment boost: Nanodroplets embedded with photosensitizer (BPD), indocyanine green (ICG) and oxygen (left) increase the oxygenation of hypoxic tumours (right), enabling oxygen-enhanced photodynamic ...
via Bing News